- Home
- SCYX vs ATRA Comparison
SCYX vs ATRA Comparison
Compare SCYX & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- ATRA
- Stock Information
- Founded
- SCYX 1999
- ATRA 2012
- Country
- SCYX United States
- ATRA United States
- Employees
- SCYX N/A
- ATRA N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCYX Health Care
- ATRA Health Care
- Exchange
- SCYX Nasdaq
- ATRA Nasdaq
- Market Cap
- SCYX 36.8M
- ATRA 40.1M
- IPO Year
- SCYX 2014
- ATRA 2014
- Fundamental
- Price
- SCYX $0.88
- ATRA $7.80
- Analyst Decision
- SCYX
- ATRA Buy
- Analyst Count
- SCYX 0
- ATRA 5
- Target Price
- SCYX N/A
- ATRA $17.75
- AVG Volume (30 Days)
- SCYX 204.8K
- ATRA 78.0K
- Earning Date
- SCYX 05-15-2025
- ATRA 05-15-2025
- Dividend Yield
- SCYX N/A
- ATRA N/A
- EPS Growth
- SCYX N/A
- ATRA N/A
- EPS
- SCYX N/A
- ATRA N/A
- Revenue
- SCYX $2,630,000.00
- ATRA $199,732,000.00
- Revenue This Year
- SCYX $460.12
- ATRA N/A
- Revenue Next Year
- SCYX $253.87
- ATRA N/A
- P/E Ratio
- SCYX N/A
- ATRA N/A
- Revenue Growth
- SCYX N/A
- ATRA 475.53
- 52 Week Low
- SCYX $0.72
- ATRA $5.01
- 52 Week High
- SCYX $2.60
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- SCYX 48.64
- ATRA 58.85
- Support Level
- SCYX $0.72
- ATRA $6.80
- Resistance Level
- SCYX $1.02
- ATRA $8.10
- Average True Range (ATR)
- SCYX 0.08
- ATRA 0.59
- MACD
- SCYX 0.00
- ATRA 0.07
- Stochastic Oscillator
- SCYX 51.70
- ATRA 82.46
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).